Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIA Trial of MK-8245 in Type 2 Diabetes Mellitus With Inadequate Glycemic Control
2008-005817-23Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-8245 with Placebo (2 arms). Primary endpoints: 24-hour Weighted Mean Glucose (24h-WMG) and Fasting Plasma Glucose. Started Nov 2008; status: terminated.
02
Drugs
mk-8245
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-005817-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005817-23.